Perrigo (PRGO) Change in Accured Expenses (2013 - 2026)
Perrigo (PRGO) posted quarterly Change in Accured Expenses of -$24.9 million for Q1 2026, up 55.61% year-over-year from -$16.0 million in Q1 2025, and down 0.81% quarter-over-quarter from -$24.7 million in Q4 2025.
Perrigo (PRGO) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Change in Accured Expenses for 14 consecutive years, with -$24.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 55.61% year-over-year to -$24.9 million; the TTM figure through Mar 2026 stood at -$32.2 million (down 455.17% YoY), while the FY2025 annual figure was -$63.4 million, down 4776.92% from the prior year.
- Change in Accured Expenses eased to -$24.9 million in Q1 2026 per PRGO's latest filing, from -$24.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $55.7 million in Q3 2023 and bottomed at -$66.0 million in Q4 2023.
- Historically, Change in Accured Expenses has averaged -$10.6 million across 5 years, with a median of -$15.1 million in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 3376.47% in 2023 and fell as far as 2969.57% in 2023.
- Perrigo's Change in Accured Expenses stood at $2.3 million in 2022, then plunged by 2969.57% to -$66.0 million in 2023, then soared by 64.09% to -$23.7 million in 2024, then slipped by 4.22% to -$24.7 million in 2025, then dropped by 0.81% to -$24.9 million in 2026.
- Business Quant data shows PRGO's Change in Accured Expenses at -$24.9 million in Q1 2026, -$24.7 million in Q4 2025, and -$15.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Perrigo | 1.91 Bn | 1.51 Bn | 313.90 Mn | -20.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -20.10 Mn |
| Jun 27, 2026 | -20.10 Mn |
| Mar 28, 2026 | -24.90 Mn |
| Mar 28, 2026 | -24.90 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Dec 31, 2025 | -24.70 Mn |
| Sep 27, 2025 | -15.10 Mn |
| Sep 27, 2025 | -15.10 Mn |
| Jun 28, 2025 | 32.50 Mn |
| Jun 28, 2025 | 32.50 Mn |
| Mar 29, 2025 | -56.10 Mn |
| Mar 29, 2025 | -56.10 Mn |
| Dec 31, 2024 | -23.70 Mn |
| Dec 31, 2024 | -23.70 Mn |
| Sep 28, 2024 | 39.30 Mn |
| Sep 28, 2024 | 39.30 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Mar 30, 2024 | -51.60 Mn |
| Mar 30, 2024 | -51.60 Mn |